Pfizer, Oxford and other Vaccines

the majority of hospitalisations are from the double vaccinated

In that particular link, yes.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

They used national linked datasets from general practice, national immunisation and SARS-CoV-2 testing, death registry and hospital episode data, in order to analyse a sample of over 6.9m vaccinated adults, of whom 5.2m had both vaccines doses, which was representative of the UK population as a whole. This sample included 2,031 Covid-19 deaths and 1,929 Covid-19 related hospital admissions, of which 81 deaths and 71 admissions occurred 14 or more days after the second vaccine dose.

‘This enormous national study of over 5 million people vaccinated with 2 doses across the UK has found that a small minority of people remain at risk of Covid-19 hospitalisation and death. Our risk calculator helps to identify those who remain most at risk post-vaccination.’

‘Our new QCovid tool, developed with the help of experts from across the UK, has been designed to identify those at high risk who may benefit from interventions such as vaccine booster doses or new treatments such as monoclonal antibodies, which can help reduce the risk of progression SARS-CoV-2 infection to serious Covid-19 outcomes.’

‘Individual risk will always depend on individual choices as well as the current prevalence of the disease, however we hope that this new tool will help shared decision making and more personalised risk assessment.’

A mobile computing application will be developed for Apple iOS and Google Android based mobile devices. This application will be targeted towards healthcare providers who make routine use of mobile devices in their daily work. The application will be capable of capturing all information required for submission to the Vaccine Adverse Event Reporting System (VAERS) and securely transmitting the information to the VAERS database. The application will also serve as a reference to healthcare providers for vaccine, vaccine safety, and other vaccination topics. No other application currently exists to provide these needed capabilities. Phase I of this project entails the design and development of the application, and will serve as the proof of principal prototype. Phase II will consist of preparing the application for broad distribution to healthcare providers. The distribution and use of this application will increase the rate of reporting to the VAERS system and will also provide higher quality, and more complete data. This will benefit public health officials in that the availability of higher quality data and enhanced surveillance will allow for better informed public health decisions.

You can now receive news updates from the MHRA and report side effects to medicines via the Yellow Card app.

You can use your YellowCard website account details on the app to report. Please download it from the Apple App Store, or Google Play Store.